Equibles does not estimate personal net worth.
Get an email with a short summary when Aclaris Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ACRS alertsKevin Balthaser is recorded as CFO at Aclaris Therapeutics, Inc. (ACRS). The newest filing on record that lists Kevin Balthaser as CFO at Aclaris Therapeutics, Inc. (ACRS) is dated April 23, 2026. Aclaris Therapeutics, Inc. reported in an 8-K filed January 6, 2023 that Kevin Balthaser was appointed Chief Financial Officer, effective January 1, 2023. Aclaris Therapeutics, Inc. reported in an 8-K filed November 22, 2022 that Kevin Balthaser was appointed Chief Financial Officer, effective January 1, 2023. The proxy statement of Aclaris Therapeutics, Inc. reports total compensation of $1,490,790 for Kevin Balthaser in fiscal 2025, including a base salary of $446,000. Disclosed compensation is on record for 3 fiscal years. Kevin Balthaser has spoken on 2 earnings calls across 1 company, most recently for Aclaris Therapeutics, Inc. on May 7, 2024. Aclaris Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Aclaris Therapeutics, Inc. includes Neal Walker (CEO, Chairman and Board Member), Douglas Manion (COO and Board Member), Douglas Manion, M.D., FRCP (C) (COO) and 4 others.
“As previously disclosed, on November 21, 2022 the Board of the Company appointed Kevin Balthaser as the Company's Chief Financial Officer, effective as of January 1, 2023.”
“On November 21, 2022, the Board appointed Kevin Balthaser as the Company's Chief Financial Officer, effective as of January 1, 2023.”
“Please note that earlier today, we issued a press release highlighting our first quarter 2024 financial results and other business matters.”
“Our financial highlights are projected on slide 25. Let us begin with our cash position. We ended Q1 with cash, cash equivalents, and marketable securities of $204 million, which compared to $230 million at year-end.”
Start not stated–present
Last confirmed April 23, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | $446,000 | $1,490,790 |
| 2024 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | $444,000 | $1,102,163 |
| 2023 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | $444,000 | $2,344,432 |
